Impact of physiologically based pharmacokinetic modeling and simulation in drug development

Drug Metabolism and Disposition

Volumn 41, Issue 12, 2013, Pages 1194-2003

  Shardlow, Carole E ^a   Generaux, Grant T ^b   Patel, Aarti H ^a   Tai, Guoying ^b   Tran, Thuy ^b   Bloomer, Jackie C ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; GSK 1; GSK 19; GSK 2; GSK 20; GSK 21; GSK 22; GSK 23; GSK 28; GSK 29; GSK 3; GSK 30; GSK 31; GSK 32; GSK 33; GSK 34; GSK 35; GSK 36; GSK 37; GSK 38; GSK 39; GSK 40; GSK 41; GSK 5; GSK 6; KETOCONAZOLE; RIFAMPICIN; RITONAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; DRUG;

AGING; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL MODEL; DECISION MAKING; DISEASES; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG INTERACTION; DRUG RESEARCH; ETHNICITY; HUMAN; KIDNEY CLEARANCE; LIVER CLEARANCE; LIVER METABOLISM; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PHYSIOLOGICALLY BASED PHARMACOKINETICS; PHYSIOLOGY; PLANNING; PREDICTION; PRIORITY JOURNAL; REGISTRATION; SIMULATION; SINGLE DRUG DOSE; METABOLISM; METHODOLOGY;

DRUG DISCOVERY; DRUG INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84888624560     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.052803     Document Type: Article

References (54)

1. Ahonen J, Olkkola KT, and Neuvonen PJ (1997) Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 51:415-419.
2. Almond LM, Yang J, Jamei M, Tucker GT, and Rostami-Hodjegan A (2009) Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Curr Drug Metab 10:420-432.
3. Benowitz N, Forsyth FP, Melmon KL, and Rowland M (1974) Lidocaine disposition kinetics in monkey and man. I. Prediction by a perfusion model. Clin Pharmacol Ther 16:87-98.
4. Bowen WP, Carey JE, Miah A, McMurray HF, Munday PW, James RS, Coleman RA, and Brown AM (2000) Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 28:781-788.
5. Center for Drug Evaluation and Research (CDER) (2003) Guidance for Industry: Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. U.S. Department of Health and Human Services, Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm072123.pdf.
6. Center for Drug Evaluation and Research (CDER) (2010) Guidance for Industry: Pharmacokinetics in Patients with Impaired Hepatic Function - Study Design, Data Analysis, and Impact on Dosing and Labeling [Draft Guidance]. Revision 1. U.S. Department of Health and Human Services, Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM204959.pdf.
7. Center for Drug Evaluation and Research (CDER) (2012) Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations [Draft Guidance], U.S. Department of Health and Human Services, Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm292362.pdf.
8. Chen EP, Tai G, and Ellens H (2013) The importance of villous physiology and morphology in mechanistic physiologically-based pharmacokinetic models. Pharm Res DOI: 10.1007/s11095-013-1161-x.
9. Chu V, Einolf HJ, Evers R, Kumar G, Moore D, Ripp S, Silva J, Sinha V, Sinz M, and Skerjanec A (2009) In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective. Drug Metab Dispos 37:1339-1354.
10. Committee for Human Medicinal Products (CHMP) (2004) Note for Guideline on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Hepatic Function. European Medicines Agency (EMA), London. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003123.pdf.
11. Committee for Human Medicinal Products (CHMP) (2005) Guideline on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Hepatic Function. European Medicines Agency (EMA), London. http://www.emea.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003122.pdf.
12. Committee for Human Medicinal Products (CHMP) (2012) Guideline on the Investigation of Drug Interactions [Final], European Medicines Agency, London. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/ 07/WC500129606.pdf.
13. De Buck SS and Mackie CE (2007) Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation. Expert Opin Drug Metab Toxicol 3:865-878.
14. de Waziers I, Cugnenc PH, Yang CS, Leroux JP, and Beaune PH (1990) Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 253:387-394.
15. Edginton AN, Theil FP, Schmitt W, and Willmann S (2008) Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 4:1143-1152.
16. Einolf HJ (2007) Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 37:1257-1294.
17. Espié P, Tytgat D, Sargentini-Maier ML, Poggesi I, and Watelet JB (2009) Physiologically based pharmacokinetics (PBPK). Drug Metab Rev 41:391-407.
18. Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, and Hyland R, et al. (2009) Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 37:1658-1666.
19. Fenneteau F, Poulin P, and Nekka F (2010) Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J Pharm Sci 99:486-514.
20. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KLR, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
21. Grillo JA, Zhao P, Bullock J, Booth BP, Lu M, Robie-Suh K, Berglund EG, Pang KS, Rahman A, and Zhang L, et al. (2012) Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharm Drug Dispos 33:99-110.
22. Harrison LI and Gibaldi M (1977) Physiologically based pharmacokinetic model for digoxin disposition in dogs and its preliminary application to humans. J Pharm Sci 66:1679-1683.
23. Hill A, van der Lugt J, Sawyer W, and Boffito M (2009) How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. AIDS 23: 2237-2245.
24. Huang S-M (2012) PBPK as a tool in regulatory review. Biopharm Drug Dispos 33:51-52.
25. Jamei M, Marciniak S, Feng K, Barnett A, Tucker GT, and Rostami-Hodjegan A (2009) The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 5:211-223.
26. Jones HM, Dickins M, Youdim K, Gosset JR, Attkins NJ, Hay TL, Gurrell IK, Logan YR, Bungay PJ, and Jones BC, et al. (2012) Application of PBPK modelling in drug discovery and development at Pfizer. Xenobiotica 42:94-106.
27. Kato M, Shitara Y, Sato H, Yoshisue K, Hirano M, Ikeda T, and Sugiyama Y (2008) The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm Res 25:1891-1901.
28. Leong R, Vieira MLT, Zhao P, Mulugeta Y, Lee CS, Huang S-M, and Burckart GJ (2012) Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin Pharmacol Ther 91:926-931.
29. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, and Polli JW (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029-1037.
30. McGinnity DF, Zhang G, Kenny JR, Hamilton GA, Otmani S, Stams KR, Haney S, Brassil P, Stresser DM, and Riley RJ (2009) Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. Drug Metab Dispos 37:1259-1268.
31. Nestorov IA (2007) Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 3:235-249.
32. Obach RS, Walsky RL, and Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255.
33. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
34. Pichette V and Leblond FA (2003) Drug metabolism in chronic renal failure. Curr Drug Metab 4:91-103.
35. Polli JW, Hussey E, Bush M, Generaux G, Smith G, Collins D, McMullen S, Turner N, and Nunez DJ (2013) Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. Xenobiotica 43:498-508.
36. Poulin P and Theil FP (2002) Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 91:1358-1370.
37. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
38. Rostami-Hodjegan A (2012) Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther 92:50-61.
39. Rostami-Hodjegan A and Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-148.
40. Rowland M, Peck C, and Tucker G (2011) Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 51:45-73.
41. Rowland Yeo KR, Aarabi M, Jamei M, and Rostami-Hodjegan A (2011a) Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev Clin Pharmacol 4:261-274.
42. Rowland Yeo KR, Walsky RL, Jamei M, Rostami-Hodjegan A, and Tucker GT (2011b) Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. Eur J Pharm Sci 43:160-173.
43. Shardlow CE, Generaux GT, MacLauchlin CC, Pons N, Skordos KW, and Bloomer JC (2011) Utilizing drug-drug interaction prediction tools during drug development: enhanced decision making based on clinical risk. Drug Metab Dispos 39:2076-2084.
44. Theil FP, Guentert TW, Haddad S, and Poulin P (2003) Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett 138:29-49.
45. Teorell T (1937) Kinetics of distribution of substances administered to the body. I. The extravascular modes of administration. Arch Int Pharmacodyn Ther 57:202-225.
46. Vilay AM, Churchwell MD, and Mueller BA (2008) Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury. Crit Care 12:235.
47. Vossen M, Sevestre M, Niederalt C, Jang IJ, Willmann S, and Edginton AN (2007) Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Theor Biol Med Model 4:13.
48. Watanabe T, Kusuhara H, Maeda K, Shitara Y, and Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652-662.
49. Xu Y, Zhou Y, Hayashi M, Shou M, and Skiles GL (2011) Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs. Drug Metab Dispos 39:1139-1148.
50. Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2008) Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 9:384-394.
51. Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, Thummel KE, and Huang SM (2009) Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol 49:351-359.
52. Zhao P, Rowland M, and Huang S-M (2012a) Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin Pharmacol Ther 92:17-20.
53. Zhao P, Vieira Mde L, Grillo JA, Song P, Wu TC, Zheng JH, Arya V, Berglund EG, Atkinson AJ, Jr, and Sugiyama Y, et al. (2012b) Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J Clin Pharmacol 52(Suppl):91S-108S
54. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, Song P, Brar SS, Madabushi R, and Wu TC, et al. (2011) Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 89:259-267.